One notable exception is the FDA-approved CAR-T target-encoded gene CD19, which is essential in 75% (9/12) of non-Hodgkin’s B-cell lymphoma cell lines, 25% (3/12) of B-cell acute lymphoblastic leukemia (B-ALL) cell lines, and 100% (3/3) of unspecified B-cell leukemia cell lines (Figure 4B, Supplementary Table S6). This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.